Table 2 Clinical, laboratory characteristics and use of anti-diabetic medications of patients randomized to oral sodium bicarbonate (Treated) or conventional therapy (controls) at study completion
From: Correction of metabolic acidosis improves insulin resistance in chronic kidney disease
Overall | Treated | Control | p-value | |
|---|---|---|---|---|
145 | 71 | 74 | ||
Body Weight, kg | 76.1 ± 12.8 | 76.3 ± 12.8 | 73.4 ± 15.0 | NS |
Systolic blood pressure, mmHg | 123 ± 17 | 125 ± 17 | 121 ± 16 | NS |
Disatolic blood pressure, mmHg | 74 ± 8 | 76 ± 8 | 72 ± 10 | NS |
Serum Bicarbonate, mEql/l | 24.2 ± 2.7 | 26.0 ± 2.0 | 22.3 ± 1.9 | 0.0001 |
Serum Gucose, mg/dl | 118 ± 29 | 110 ± 32 | 127 ± 24 | 0.0001 |
HbA1C % | 7.2 ± 2.9 | 6.7 ± 0.9 | 7.7 ± 3.7 | 0.028 |
Creatinine Clearance, ml/min | 30 ± 16 | 32 ± 15 | 31 ± 16 | NS |
Homa-IR | 6.52 ± 1.8 | 6.1 ± 1.5 | 7.0 ± 2.0 | 0.003 |
HOMA % B | 52 ± 20 | 55 ± 18 | 49 ± 21 | 0.015 |
Serum insulin, mcIU | 16.4 ± 6.6 | 13.4 ± 5.2 | 19.9 ± 6.3 | 0.0001 |
Antidiabetic medications | ||||
Biguanides, number (%) | 89 (61.4) | 45 (63.3) | 44 (59.4) | NS |
dose, mg/day | 1570 ± 517 | 1377 ± 457 | 1615 ± 550 | 0.005 |
Solfonylureas, number (%) | 40 (27.6) | 12 (16.9) | 28 (37.8) | 0.009 |
dose, mg/day | 5.05 ± 1.29 | 4.89 ± 1.7 | 5.20 ± 1.07 | 0.033 |
Meglitinides, number (%) | 36 (24.8) | 16 (22.5) | 20 (27) | NS |
dose, mg/day | 3.13 ± 1.35 | 3.52 ± 0.91 | 2.76 ± 1.59 | 0.0001 |
Use of > 1 medication, number (%) | 28 (19.3) | 12 (16.9) | 16 (21.6) | NS |